CIC has evaluated a wide range of other novel molecules, establishing proof-of-principle for a number of them, including:

Monoclonal antibodies

• TSLP    (tezepelumab, N Engl J Med. 2014; 370(22): 2102-10)
• IL-13    (Am J Respir Crit Care Med Vol 183. pp 1007–1014, 2011)
• M1-prime    (quilizumab, Sci. Transl. Med. 6, 243ra85 (2014))
• IgE    (ligelizumab, J Allergy Clin Immunol. 2016 Oct;138(4):1051-1059)
• C5a    (eculizumab, Expert Opin Biol Ther. 2012 Apr;12(4):529-37)
• OX40L    (Clin Exp Allergy. 2014 Jan;44(1):29-37)
• IL-9    (BMC Pulm Med. 2011 Feb 28;11:14)
• IL-5Ra

Small molecules

• CysLT1/2 antagonist    (Allergy 2016 Dec;71(12):1721-1727.)
• CXCR2 antagonist    (Pulm Pharmacol Ther. 2016 Dec;41:34-39)
• GCR agonist    (Am J Respir Crit Care Med. 2015 Jan 15;191(2):161-7)
• Olodaterol    (J Allergy Clin Immunol. 2009 Dec;124(6):1217-21)
• Nicotinic receptor agonist    (Can Respir J. 2015 Jul-Aug; 22(4): 230–234)
• Amino acid peptide AIM102

Antisense

• IL-4R
• ASM8 (CCR3/Bc)    (Am J Respir Crit Care Med. 2008 May 1;177(9):952-8  &  Allergy. 2011 Sep;66(9):1242-8)